Lower baseline ALT cut-off values and HBV DNA levels better differentiate HBeAg- chronic hepatitis B patients from...

Area of Science:

• Hepatology
• Virology
• Clinical Diagnostics

Background:

• Distinguishing between chronic hepatitis B (CHB) patients and inactive carriers is crucial for appropriate management.
• Current diagnostic criteria may require refinement to improve accuracy in patient stratification.

Purpose of the Study:

• To evaluate new alanine aminotransferase (ALT) cut-off values and baseline hepatitis B virus (HBV) DNA levels for differentiating HBeAg(-) CHB patients from inactive carriers.
• To assess the diagnostic accuracy of these updated parameters.

Main Methods:

• A cohort of 91 patients, including HBeAg(+) CHB, inactive carriers, and HBeAg(-) CHB, were followed for 2 years.
• HBV DNA levels were measured using a PCR-based assay, and ALT was tested using new cut-off values (30 IU/L for males, 19 IU/L for females).
• Discriminant analysis was employed to calculate diagnostic accuracy, sensitivity, specificity, and predictive values.

Main Results:

• A lowest optimal HBV DNA level of 50,000 copies/mL differentiated HBeAg(-) CHB patients from inactive carriers using revised ALT cut-offs.
• Diagnostic accuracy for identifying inactive carriers with HBV DNA < 50,000 copies/mL was 91%, similar to the previous 100,000 copies/mL cut-off.
• Specific ALT and HBV DNA thresholds (ALT < 30/19 IU/L and HBV DNA < 100,000 copies/mL) indicated a low risk (5%) of CHB, while higher values (ALT > 30/19 IU/L and HBV DNA > 100,000 copies/mL) showed an 86% risk.

Conclusions:

• New ALT cut-off values combined with HBV DNA levels, as proposed by AASLD and NIH consensus, appear suitable for characterizing inactive carriers.
• These updated criteria enhance the ability to differentiate between active CHB and inactive carrier states.
• The findings support the use of these refined parameters in clinical practice for hepatitis B management.